Promoter hypermethylation of FBXO32, a novel TGF-Β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer

Research output: Contribution to journalArticle

80 Scopus citations
Original languageEnglish (US)
Pages (from-to)414-425
Number of pages12
JournalLaboratory Investigation
Volume90
Issue number3
DOIs
StatePublished - Mar 1 2010

Cite this

Chou, J. L., Su, H. Y., Chen, L. Y., Liao, Y. P., Hartman-Frey, C., Lai, Y. H., Yang, H. W., Deatherage, D. E., Kuo, C. T., Huang, Y. W., Yan, P. S., Hsiao, S. H., Tai, C. K., Lin, H. J. L., Davuluri, R. V., Chao, T. K., Nephew, K. P., Huang, T. H. M., Lai, H. C., & Chan, M. W. Y. (2010). Promoter hypermethylation of FBXO32, a novel TGF-Β/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Laboratory Investigation, 90(3), 414-425. https://doi.org/10.1038/labinvest.2009.138